About
Axor Biosystems was founded in Oct 2023 to develop and commercialize a microplate based miniaturized electrophoresis platform, to purify sub-components from reaction products with higher accuracy and precision.
Embedded Files
Motivation
Motivation
The founders of Axor witnessed firsthand the explosion of genomics data—a revolution they helped ignite. But with this surge came an overwhelming crisis: the relentless volume of samples needed to feed high-throughput sequencing systems was outpacing the capacity to process these samples. Labs were drowning in complex workflows, crippled by the staggering costs and inefficiencies of traditional sample preparation. This bottleneck wasn’t just an inconvenience; it was a barrier halting critical data generation and choking the flow of scientific breakthroughs when the world needed them most.
Our mission became: To create a much needed solution, to create a single system — with pre-prepared, ready-to-use consumables and an automatable process, to eliminate the tangled web of equipment, protocols, and consumables that were suffocating progress. After an exhaustive exploration of alternatives, the solution seemed obvious. By embedding electrophoresis within laboratory microplates, we could harness its unmatched versatility, power and precision, to address the complexity of multi-step sample prep. and biomolecule analysis.
Founding team
Founding team
Brett Anderson, the CTO, and Abizar Lakdawalla, the CEO, worked together at Apton Biosystems to develop an ultra-high throughput Next Generation Sequencing & Proteomics platform based on a novel sub-diffraction imaging technology invented by Bryan Staker, co-founder and CTO of Apton.
The co-founders have >25 years of experience in developing, building and launching systems & applications in genomics such as microfluidic reaction processors, next generation sequencing systems, infectious disease detection panels, liquid biopsies for cancer and sepsis, cell & gene therapy products, single-molecule nanopore-based sequencing at start-ups (Apton, IDbyDNA, Proxeom, Resilience, Synthego, Ultima Genomics, …) and at larger companies such as Illumina and Thermo Fisher Scientific. These products were well received by customers and have cumulatively generated >$5B in revenues.
Abizar has worked on single cell toxicology systems, automated platforms for immunohistochemistry and in situ hybridization, microfluidic devices for integrated PCR and Sanger sequencing, and Next Generation Sequencing platforms. He has also helped develop assays for liquid biopsy, sepsis, exome resequencing, and for reproductive health applications. He used an extensive amount of electrophoresis resulting in increasing dissatisfaction with the existing electrophoresis processes.
Brett is a single-molecule bioengineer by training with a strong background in developing firmware and software for complex life sciences tools, from single-molecule nanopore sequencing to brain implant monitors.
He likes integrating real-time imaging to steer biomolecules through meandering channels under the influence of hard-to-resist electrical currents.
Page updated
Report abuse